Project Grant R44CA239461

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,304,828 to The Washington University in St. Louis to conduct a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The research aims to assess the cytotoxic and immunomodulatory effects of (R)-9B, a small molecule that inhibits the ACK1...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The Johns Hopkins University is valued at $545,078 and will fund research to investigate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy (PSMA-RPT) on glutamine metabolism in experimental models of prostate cancer (PC) and renal cell carcinoma (RCC). The research aims to evaluate how PSMA-RPT affects glutaminolysis as monotherapy and in combination with...

This $692,072 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund the development of a novel theranostic platform using PSMA-targeted poly(amidoamine) (PAMAM) dendrimers for the management of prostate cancer. The key products to be delivered include: PSMA-targeted theranostic agents that enable highly specific targeting, quantitative PET/CT imaging for patient selection, and delivery of potent antimitotic agents....

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $571,271 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Texas Health Science Center at Houston (UTHealth) to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The key goals of the 5-year project are to: (1) synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate to selectively deliver the...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $602,361 to Yale University to develop deep learning-based models for personalized treatment planning of Prostate-Specific Membrane Antigen (PSMA) Radioligand Therapy (RPT) for metastatic castration-resistant prostate cancer. The project aims to leverage imaging data from pre-treatment PSMA-PET scans and during-treatment SPECT scans to build predictive models that can estimate...

This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...